Measuring Cancer by Its Chaos, Not Its Quantity

Wed, 10 Jun 2026 04:11:11 +0000

The most promising liquid biopsy tests detect cancer best when it’s already at Stage IV — which is roughly the opposite of what early detection means. GRAIL’s Galleri test, the most prominent multi-cancer screening product on the market, achieves 90% sensitivity at Stage IV. At Stage I, that number drops to 18% across all cancer types. You are more likely to miss an early-stage cancer than catch it. The test is, functionally, a very expensive way to confirm what a symptomatic patient probably already suspects.

Epigenetics on BRYSGO

Measuring Cancer by Its Chaos, Not Its Quantity